Emergent BioSolutions Inc. (NYSE: EBS) Stock Competitors & Peer Comparison
See EBS's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for EBS and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| EBS | $6.92 | +1.91% | 354M | 4.76 | $1.44 | N/A |
| TAK | $18.52 | -1.83% | 60.2B | 13.59 | $1.39 | +3.34% |
| TEVA | $39.90 | +1.81% | 45.3B | 13.27 | $2.93 | N/A |
| HLN | $9.01 | -2.75% | 40.4B | 18.78 | $0.49 | +2.16% |
| ZTS | $70.47 | -0.82% | 29.9B | 10.85 | $6.58 | +2.93% |
| VTRS | $17.91 | +0.45% | 21.3B | 7.25 | $2.52 | +2.62% |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| ELAN | $22.42 | +0.49% | 11.2B | 21.17 | $1.06 | N/A |
| RDY | $12.89 | +5.18% | 10.4B | 20.52 | $0.61 | +0.66% |
Stock Comparison
Takeda Pharmaceutical Company Limited (NYSE: TAK)
EBS vs TAK Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, TAK has a market cap of 60.2B. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while TAK trades at $18.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas TAK's P/E ratio is 13.59. In terms of profitability, EBS's ROE is -0.36%, compared to TAK's ROE of +0.02%. Regarding short-term risk, EBS is more volatile compared to TAK. This indicates higher risk in terms of short-term price fluctuations for EBS.Check TAK's competition here
Teva Pharmaceutical Industries Limited (NYSE: TEVA)
EBS vs TEVA Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, TEVA has a market cap of 45.3B. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while TEVA trades at $39.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas TEVA's P/E ratio is 13.27. In terms of profitability, EBS's ROE is -0.36%, compared to TEVA's ROE of +0.09%. Regarding short-term risk, EBS is less volatile compared to TEVA. This indicates lower risk in terms of short-term price fluctuations for EBS.Check TEVA's competition here
Haleon plc (NYSE: HLN)
EBS vs HLN Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, HLN has a market cap of 40.4B. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while HLN trades at $9.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas HLN's P/E ratio is 18.78. In terms of profitability, EBS's ROE is -0.36%, compared to HLN's ROE of +0.17%. Regarding short-term risk, EBS is more volatile compared to HLN. This indicates higher risk in terms of short-term price fluctuations for EBS.Check HLN's competition here
Zoetis Inc. (NYSE: ZTS)
EBS vs ZTS Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, ZTS has a market cap of 29.9B. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while ZTS trades at $70.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas ZTS's P/E ratio is 10.85. In terms of profitability, EBS's ROE is -0.36%, compared to ZTS's ROE of +0.69%. Regarding short-term risk, EBS is more volatile compared to ZTS. This indicates higher risk in terms of short-term price fluctuations for EBS.Check ZTS's competition here
Viatris Inc. (NASDAQ: VTRS)
EBS vs VTRS Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, VTRS has a market cap of 21.3B. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while VTRS trades at $17.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas VTRS's P/E ratio is 7.25. In terms of profitability, EBS's ROE is -0.36%, compared to VTRS's ROE of -0.03%. Regarding short-term risk, EBS is less volatile compared to VTRS. This indicates lower risk in terms of short-term price fluctuations for EBS.Check VTRS's competition here
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI)
EBS vs ITCI Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas ITCI's P/E ratio is -180.64. In terms of profitability, EBS's ROE is -0.36%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, EBS is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for EBS.Check ITCI's competition here
Catalent, Inc. (NYSE: CTLT)
EBS vs CTLT Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas CTLT's P/E ratio is -27.84. In terms of profitability, EBS's ROE is -0.36%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, EBS is more volatile compared to CTLT. This indicates higher risk in terms of short-term price fluctuations for EBS.Check CTLT's competition here
Elanco Animal Health Incorporated (NYSE: ELAN)
EBS vs ELAN Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, ELAN has a market cap of 11.2B. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while ELAN trades at $22.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas ELAN's P/E ratio is 21.17. In terms of profitability, EBS's ROE is -0.36%, compared to ELAN's ROE of -0.03%. Regarding short-term risk, EBS is more volatile compared to ELAN. This indicates higher risk in terms of short-term price fluctuations for EBS.Check ELAN's competition here
Dr. Reddy's Laboratories Limited (NYSE: RDY)
EBS vs RDY Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, RDY has a market cap of 10.4B. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while RDY trades at $12.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas RDY's P/E ratio is 20.52. In terms of profitability, EBS's ROE is -0.36%, compared to RDY's ROE of +0.09%. Regarding short-term risk, EBS is more volatile compared to RDY. This indicates higher risk in terms of short-term price fluctuations for EBS.Check RDY's competition here
Alkermes plc (NASDAQ: ALKS)
EBS vs ALKS Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, ALKS has a market cap of 6.7B. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while ALKS trades at $40.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas ALKS's P/E ratio is 42.26. In terms of profitability, EBS's ROE is -0.36%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, EBS is more volatile compared to ALKS. This indicates higher risk in terms of short-term price fluctuations for EBS.Check ALKS's competition here
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX)
EBS vs AMRX Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, AMRX has a market cap of 6.5B. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while AMRX trades at $20.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas AMRX's P/E ratio is 22.78. In terms of profitability, EBS's ROE is -0.36%, compared to AMRX's ROE of -3.27%. Regarding short-term risk, EBS is less volatile compared to AMRX. This indicates lower risk in terms of short-term price fluctuations for EBS.Check AMRX's competition here
Lantheus Holdings, Inc. (NASDAQ: LNTH)
EBS vs LNTH Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, LNTH has a market cap of 6.5B. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while LNTH trades at $99.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas LNTH's P/E ratio is 16.76. In terms of profitability, EBS's ROE is -0.36%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, EBS is more volatile compared to LNTH. This indicates higher risk in terms of short-term price fluctuations for EBS.Check LNTH's competition here
Indivior Pharmaceuticals Inc (NASDAQ: INDV)
EBS vs INDV Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, INDV has a market cap of 4.6B. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while INDV trades at $36.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas INDV's P/E ratio is 10.10. In terms of profitability, EBS's ROE is -0.36%, compared to INDV's ROE of -2.16%. Regarding short-term risk, EBS is less volatile compared to INDV. This indicates lower risk in terms of short-term price fluctuations for EBS.Check INDV's competition here
Alvotech (NASDAQ: ALVOW)
EBS vs ALVOW Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, ALVOW has a market cap of 3.5B. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while ALVOW trades at $0.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas ALVOW's P/E ratio is 55.38. In terms of profitability, EBS's ROE is -0.36%, compared to ALVOW's ROE of +0.77%. Regarding short-term risk, EBS is more volatile compared to ALVOW. This indicates higher risk in terms of short-term price fluctuations for EBS.Check ALVOW's competition here
Regencell Bioscience Holdings Limited (NASDAQ: RGC)
EBS vs RGC Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, RGC has a market cap of 3.1B. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while RGC trades at $6.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas RGC's P/E ratio is -436.62. In terms of profitability, EBS's ROE is -0.36%, compared to RGC's ROE of -2.32%. Regarding short-term risk, EBS is more volatile compared to RGC. This indicates higher risk in terms of short-term price fluctuations for EBS.Check RGC's competition here
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)
EBS vs SUPN Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, SUPN has a market cap of 2.6B. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while SUPN trades at $43.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas SUPN's P/E ratio is 14.58. In terms of profitability, EBS's ROE is -0.36%, compared to SUPN's ROE of -0.10%. Regarding short-term risk, EBS is less volatile compared to SUPN. This indicates lower risk in terms of short-term price fluctuations for EBS.Check SUPN's competition here
HUTCHMED (China) Limited (NASDAQ: HCM)
EBS vs HCM Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, HCM has a market cap of 2.5B. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while HCM trades at $14.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas HCM's P/E ratio is 5.30. In terms of profitability, EBS's ROE is -0.36%, compared to HCM's ROE of +0.01%. Regarding short-term risk, EBS is more volatile compared to HCM. This indicates higher risk in terms of short-term price fluctuations for EBS.Check HCM's competition here
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
EBS vs DCPH Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas DCPH's P/E ratio is -11.58. In terms of profitability, EBS's ROE is -0.36%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, EBS is more volatile compared to DCPH. This indicates higher risk in terms of short-term price fluctuations for EBS.Check DCPH's competition here
Bausch Health Companies Inc. (NYSE: BHC)
EBS vs BHC Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, BHC has a market cap of 2.2B. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while BHC trades at $5.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas BHC's P/E ratio is 1.47. In terms of profitability, EBS's ROE is -0.36%, compared to BHC's ROE of +0.89%. Regarding short-term risk, EBS is more volatile compared to BHC. This indicates higher risk in terms of short-term price fluctuations for EBS.Check BHC's competition here
Avadel Pharmaceuticals plc (NASDAQ: AVDL)
EBS vs AVDL Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, EBS's ROE is -0.36%, compared to AVDL's ROE of +0.05%. Regarding short-term risk, EBS is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for EBS.Check AVDL's competition here
Trulieve Cannabis Corp. (NYSE: TRLV)
EBS vs TRLV Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, TRLV has a market cap of 2.1B. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while TRLV trades at $12.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas TRLV's P/E ratio is -5.02. In terms of profitability, EBS's ROE is -0.36%, compared to TRLV's ROE of -0.44%. Regarding short-term risk, EBS is more volatile compared to TRLV. This indicates higher risk in terms of short-term price fluctuations for EBS.Check TRLV's competition here
Perrigo Company plc (NYSE: PRGO)
EBS vs PRGO Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, PRGO has a market cap of 2.1B. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while PRGO trades at $15.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas PRGO's P/E ratio is 6.03. In terms of profitability, EBS's ROE is -0.36%, compared to PRGO's ROE of -0.56%. Regarding short-term risk, EBS is more volatile compared to PRGO. This indicates higher risk in terms of short-term price fluctuations for EBS.Check PRGO's competition here
Alvotech (NASDAQ: ALVO)
EBS vs ALVO Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, ALVO has a market cap of 2.1B. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while ALVO trades at $6.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas ALVO's P/E ratio is -10.42. In terms of profitability, EBS's ROE is -0.36%, compared to ALVO's ROE of +0.77%. Regarding short-term risk, EBS is less volatile compared to ALVO. This indicates lower risk in terms of short-term price fluctuations for EBS.Check ALVO's competition here
Embecta Corp. (NASDAQ: EMBCV)
EBS vs EMBCV Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas EMBCV's P/E ratio is N/A. In terms of profitability, EBS's ROE is -0.36%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, EBS is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for EBS.Check EMBCV's competition here
Dynavax Technologies Corporation (NASDAQ: DVAX)
EBS vs DVAX Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas DVAX's P/E ratio is -41.89. In terms of profitability, EBS's ROE is -0.36%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, EBS is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for EBS.Check DVAX's competition here
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)
EBS vs ANIP Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, ANIP has a market cap of 1.7B. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while ANIP trades at $72.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas ANIP's P/E ratio is 9.10. In terms of profitability, EBS's ROE is -0.36%, compared to ANIP's ROE of +0.19%. Regarding short-term risk, EBS is less volatile compared to ANIP. This indicates lower risk in terms of short-term price fluctuations for EBS.Check ANIP's competition here
Eton Pharmaceuticals, Inc. (NASDAQ: ETON)
EBS vs ETON Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, ETON has a market cap of 1.6B. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while ETON trades at $58.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas ETON's P/E ratio is 155.74. In terms of profitability, EBS's ROE is -0.36%, compared to ETON's ROE of +0.40%. Regarding short-term risk, EBS is less volatile compared to ETON. This indicates lower risk in terms of short-term price fluctuations for EBS.Check ETON's competition here
Taro Pharmaceutical Industries Ltd. (NYSE: TARO)
EBS vs TARO Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas TARO's P/E ratio is 30.05. In terms of profitability, EBS's ROE is -0.36%, compared to TARO's ROE of +0.03%. Regarding short-term risk, EBS is more volatile compared to TARO. This indicates higher risk in terms of short-term price fluctuations for EBS.Check TARO's competition here
Phibro Animal Health Corporation (NASDAQ: PAHC)
EBS vs PAHC Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, PAHC has a market cap of 1.4B. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while PAHC trades at $35.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas PAHC's P/E ratio is 12.18. In terms of profitability, EBS's ROE is -0.36%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, EBS is less volatile compared to PAHC. This indicates lower risk in terms of short-term price fluctuations for EBS.Check PAHC's competition here
Cronos Group Inc. (NASDAQ: CRON)
EBS vs CRON Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, CRON has a market cap of 1.3B. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while CRON trades at $3.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas CRON's P/E ratio is 17.46. In terms of profitability, EBS's ROE is -0.36%, compared to CRON's ROE of +0.06%. Regarding short-term risk, EBS is more volatile compared to CRON. This indicates higher risk in terms of short-term price fluctuations for EBS.Check CRON's competition here
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH)
EBS vs AMPH Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, AMPH has a market cap of 1.2B. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while AMPH trades at $26.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas AMPH's P/E ratio is 9.35. In terms of profitability, EBS's ROE is -0.36%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, EBS is less volatile compared to AMPH. This indicates lower risk in terms of short-term price fluctuations for EBS.Check AMPH's competition here
Harrow Health, Inc. (NASDAQ: HROW)
EBS vs HROW Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, HROW has a market cap of 1.2B. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while HROW trades at $31.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas HROW's P/E ratio is -31.92. In terms of profitability, EBS's ROE is -0.36%, compared to HROW's ROE of -1.04%. Regarding short-term risk, EBS is more volatile compared to HROW. This indicates higher risk in terms of short-term price fluctuations for EBS.Check HROW's competition here
Pacira BioSciences, Inc. (NASDAQ: PCRX)
EBS vs PCRX Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, PCRX has a market cap of 998.7M. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while PCRX trades at $25.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas PCRX's P/E ratio is 9.77. In terms of profitability, EBS's ROE is -0.36%, compared to PCRX's ROE of +0.02%. Regarding short-term risk, EBS is more volatile compared to PCRX. This indicates higher risk in terms of short-term price fluctuations for EBS.Check PCRX's competition here
PetIQ, Inc. (NASDAQ: PETQ)
EBS vs PETQ Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas PETQ's P/E ratio is 83.73. In terms of profitability, EBS's ROE is -0.36%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, EBS is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for EBS.Check PETQ's competition here
Collegium Pharmaceutical, Inc. (NASDAQ: COLL)
EBS vs COLL Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, COLL has a market cap of 734M. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while COLL trades at $21.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas COLL's P/E ratio is 2.84. In terms of profitability, EBS's ROE is -0.36%, compared to COLL's ROE of +0.16%. Regarding short-term risk, EBS is less volatile compared to COLL. This indicates lower risk in terms of short-term price fluctuations for EBS.Check COLL's competition here
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)
EBS vs IRWD Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, IRWD has a market cap of 678.2M. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while IRWD trades at $4.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas IRWD's P/E ratio is 5.28. In terms of profitability, EBS's ROE is -0.36%, compared to IRWD's ROE of -0.57%. Regarding short-term risk, EBS is more volatile compared to IRWD. This indicates higher risk in terms of short-term price fluctuations for EBS.Check IRWD's competition here
Aquestive Therapeutics, Inc. (NASDAQ: AQST)
EBS vs AQST Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, AQST has a market cap of 596M. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while AQST trades at $4.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas AQST's P/E ratio is -7.31. In terms of profitability, EBS's ROE is -0.36%, compared to AQST's ROE of +2.44%. Regarding short-term risk, EBS is less volatile compared to AQST. This indicates lower risk in terms of short-term price fluctuations for EBS.Check AQST's competition here
BioDelivery Sciences International, Inc. (NASDAQ: BDSI)
EBS vs BDSI Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas BDSI's P/E ratio is 6.82. In terms of profitability, EBS's ROE is -0.36%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, EBS is more volatile compared to BDSI. This indicates higher risk in terms of short-term price fluctuations for EBS.Check BDSI's competition here
Evotec SE (NASDAQ: EVO)
EBS vs EVO Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, EVO has a market cap of 564.8M. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while EVO trades at $1.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas EVO's P/E ratio is -2.25. In terms of profitability, EBS's ROE is -0.36%, compared to EVO's ROE of -0.27%. Regarding short-term risk, EBS is more volatile compared to EVO. This indicates higher risk in terms of short-term price fluctuations for EBS.Check EVO's competition here
Glass House Brands Inc (NYSE: GLAS)
EBS vs GLAS Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, GLAS has a market cap of 529.2M. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while GLAS trades at $6.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas GLAS's P/E ratio is -12.22. In terms of profitability, EBS's ROE is -0.36%, compared to GLAS's ROE of -0.51%. Regarding short-term risk, EBS is less volatile compared to GLAS. This indicates lower risk in terms of short-term price fluctuations for EBS.Check GLAS's competition here
Evolus, Inc. (NASDAQ: EOLS)
EBS vs EOLS Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, EOLS has a market cap of 524.2M. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while EOLS trades at $7.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas EOLS's P/E ratio is -25.21. In terms of profitability, EBS's ROE is -0.36%, compared to EOLS's ROE of +1.23%. Regarding short-term risk, EBS is more volatile compared to EOLS. This indicates higher risk in terms of short-term price fluctuations for EBS.Check EOLS's competition here
Kamada Ltd. (NASDAQ: KMDA)
EBS vs KMDA Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, KMDA has a market cap of 497.3M. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while KMDA trades at $8.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas KMDA's P/E ratio is 22.68. In terms of profitability, EBS's ROE is -0.36%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, EBS is more volatile compared to KMDA. This indicates higher risk in terms of short-term price fluctuations for EBS.Check KMDA's competition here
Alpha Teknova, Inc. (NASDAQ: TKNO)
EBS vs TKNO Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, TKNO has a market cap of 493.2M. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while TKNO trades at $9.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas TKNO's P/E ratio is -29.68. In terms of profitability, EBS's ROE is -0.36%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, EBS is less volatile compared to TKNO. This indicates lower risk in terms of short-term price fluctuations for EBS.Check TKNO's competition here
Tilray Brands, Inc. (NASDAQ: TLRY)
EBS vs TLRY Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, TLRY has a market cap of 449.6M. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while TLRY trades at $3.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas TLRY's P/E ratio is -3.71. In terms of profitability, EBS's ROE is -0.36%, compared to TLRY's ROE of -0.08%. Regarding short-term risk, EBS is more volatile compared to TLRY. This indicates higher risk in terms of short-term price fluctuations for EBS.Check TLRY's competition here
Canopy Growth Corporation (NASDAQ: CGC)
EBS vs CGC Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, CGC has a market cap of 390.7M. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while CGC trades at $0.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas CGC's P/E ratio is -2.07. In terms of profitability, EBS's ROE is -0.36%, compared to CGC's ROE of -0.33%. Regarding short-term risk, EBS is more volatile compared to CGC. This indicates higher risk in terms of short-term price fluctuations for EBS.Check CGC's competition here
Alimera Sciences, Inc. (NASDAQ: ALIM)
EBS vs ALIM Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas ALIM's P/E ratio is 5.28. In terms of profitability, EBS's ROE is -0.36%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, EBS is more volatile compared to ALIM. This indicates higher risk in terms of short-term price fluctuations for EBS.Check ALIM's competition here
Landec Corporation (NASDAQ: LNDC)
EBS vs LNDC Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas LNDC's P/E ratio is -4.04. In terms of profitability, EBS's ROE is -0.36%, compared to LNDC's ROE of +6.44%. Regarding short-term risk, EBS is less volatile compared to LNDC. This indicates lower risk in terms of short-term price fluctuations for EBS.Check LNDC's competition here
Aurora Cannabis Inc. (NASDAQ: ACB)
EBS vs ACB Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, ACB has a market cap of 253.3M. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while ACB trades at $4.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas ACB's P/E ratio is -2.95. In terms of profitability, EBS's ROE is -0.36%, compared to ACB's ROE of -0.21%. Regarding short-term risk, EBS is more volatile compared to ACB. This indicates higher risk in terms of short-term price fluctuations for EBS.Check ACB's competition here
SIGA Technologies, Inc. (NASDAQ: SIGA)
EBS vs SIGA Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, SIGA has a market cap of 248.2M. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while SIGA trades at $3.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas SIGA's P/E ratio is 12.81. In terms of profitability, EBS's ROE is -0.36%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, EBS is less volatile compared to SIGA. This indicates lower risk in terms of short-term price fluctuations for EBS.Check SIGA's competition here
Lifecore Biomedical, Inc. (NASDAQ: LFCR)
EBS vs LFCR Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, LFCR has a market cap of 244.6M. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while LFCR trades at $6.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas LFCR's P/E ratio is -5.13. In terms of profitability, EBS's ROE is -0.36%, compared to LFCR's ROE of -3.77%. Regarding short-term risk, EBS is more volatile compared to LFCR. This indicates higher risk in terms of short-term price fluctuations for EBS.Check LFCR's competition here
Shineco, Inc. (NASDAQ: TYHT)
EBS vs TYHT Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas TYHT's P/E ratio is -1.61. In terms of profitability, EBS's ROE is -0.36%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, EBS is less volatile compared to TYHT. This indicates lower risk in terms of short-term price fluctuations for EBS.Check TYHT's competition here
Cardiol Therapeutics Inc. (NASDAQ: CRDL)
EBS vs CRDL Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, CRDL has a market cap of 194.8M. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while CRDL trades at $1.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas CRDL's P/E ratio is -6.73. In terms of profitability, EBS's ROE is -0.36%, compared to CRDL's ROE of -1.94%. Regarding short-term risk, EBS is more volatile compared to CRDL. This indicates higher risk in terms of short-term price fluctuations for EBS.Check CRDL's competition here
Organogenesis Holdings Inc. (NASDAQ: ORGO)
EBS vs ORGO Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, ORGO has a market cap of 177.6M. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while ORGO trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas ORGO's P/E ratio is 46.00. In terms of profitability, EBS's ROE is -0.36%, compared to ORGO's ROE of -0.24%. Regarding short-term risk, EBS is less volatile compared to ORGO. This indicates lower risk in terms of short-term price fluctuations for EBS.Check ORGO's competition here
Recro Pharma, Inc. (NASDAQ: REPH)
EBS vs REPH Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas REPH's P/E ratio is -8.04. In terms of profitability, EBS's ROE is -0.36%, compared to REPH's ROE of -0.22%. Regarding short-term risk, EBS is less volatile compared to REPH. This indicates lower risk in terms of short-term price fluctuations for EBS.Check REPH's competition here
Journey Medical Corporation (NASDAQ: DERM)
EBS vs DERM Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, DERM has a market cap of 177M. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while DERM trades at $6.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas DERM's P/E ratio is -29.23. In terms of profitability, EBS's ROE is -0.36%, compared to DERM's ROE of -0.20%. Regarding short-term risk, EBS is more volatile compared to DERM. This indicates higher risk in terms of short-term price fluctuations for EBS.Check DERM's competition here
Theratechnologies Inc. (NASDAQ: THTX)
EBS vs THTX Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas THTX's P/E ratio is -28.83. In terms of profitability, EBS's ROE is -0.36%, compared to THTX's ROE of +0.36%. Regarding short-term risk, EBS is more volatile compared to THTX. This indicates higher risk in terms of short-term price fluctuations for EBS.Check THTX's competition here
Organigram Global Inc. (NASDAQ: OGI)
EBS vs OGI Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, OGI has a market cap of 152.7M. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while OGI trades at $1.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas OGI's P/E ratio is 2.44. In terms of profitability, EBS's ROE is -0.36%, compared to OGI's ROE of +0.21%. Regarding short-term risk, EBS is less volatile compared to OGI. This indicates lower risk in terms of short-term price fluctuations for EBS.Check OGI's competition here
Assertio Holdings, Inc. (NASDAQ: ASRT)
EBS vs ASRT Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while ASRT trades at $23.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas ASRT's P/E ratio is -7.10. In terms of profitability, EBS's ROE is -0.36%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, EBS is more volatile compared to ASRT. This indicates higher risk in terms of short-term price fluctuations for EBS.Check ASRT's competition here
Societal CDMO, Inc. (NASDAQ: SCTL)
EBS vs SCTL Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas SCTL's P/E ratio is -7.86. In terms of profitability, EBS's ROE is -0.36%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, EBS is more volatile compared to SCTL. This indicates higher risk in terms of short-term price fluctuations for EBS.Check SCTL's competition here
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)
EBS vs CPIX Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, CPIX has a market cap of 115.7M. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while CPIX trades at $7.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas CPIX's P/E ratio is -19.30. In terms of profitability, EBS's ROE is -0.36%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, EBS is less volatile compared to CPIX. This indicates lower risk in terms of short-term price fluctuations for EBS.Check CPIX's competition here
Procaps Group S.A. (NASDAQ: PROC)
EBS vs PROC Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas PROC's P/E ratio is 1.53. In terms of profitability, EBS's ROE is -0.36%, compared to PROC's ROE of -2.22%. Regarding short-term risk, EBS is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for EBS.Check PROC's competition here
OptiNose, Inc. (NASDAQ: OPTN)
EBS vs OPTN Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas OPTN's P/E ratio is -4.42. In terms of profitability, EBS's ROE is -0.36%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, EBS is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for EBS.Check OPTN's competition here
Zomedica Corp. (AMEX: ZOM)
EBS vs ZOM Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas ZOM's P/E ratio is -1.62. In terms of profitability, EBS's ROE is -0.36%, compared to ZOM's ROE of -0.17%. Regarding short-term risk, EBS is less volatile compared to ZOM. This indicates lower risk in terms of short-term price fluctuations for EBS.Check ZOM's competition here
Upexi, Inc. (NASDAQ: GRVI)
EBS vs GRVI Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas GRVI's P/E ratio is 26.05. In terms of profitability, EBS's ROE is -0.36%, compared to GRVI's ROE of -4.51%. Regarding short-term risk, EBS is less volatile compared to GRVI. This indicates lower risk in terms of short-term price fluctuations for EBS.Check GRVI's competition here
BGM Group Ltd. (NASDAQ: BGM)
EBS vs BGM Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, BGM has a market cap of 88.8M. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while BGM trades at $0.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas BGM's P/E ratio is -1.46. In terms of profitability, EBS's ROE is -0.36%, compared to BGM's ROE of -0.05%. Regarding short-term risk, EBS is less volatile compared to BGM. This indicates lower risk in terms of short-term price fluctuations for EBS.Check BGM's competition here
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)
EBS vs ZYNE Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, EBS's ROE is -0.36%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, EBS is less volatile compared to ZYNE. This indicates lower risk in terms of short-term price fluctuations for EBS.Check ZYNE's competition here
Silver Spike Investment Corp. (NASDAQ: SSIC)
EBS vs SSIC Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas SSIC's P/E ratio is 11.93. In terms of profitability, EBS's ROE is -0.36%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, EBS is more volatile compared to SSIC. This indicates higher risk in terms of short-term price fluctuations for EBS.Check SSIC's competition here
Talphera, Inc. (NASDAQ: TLPH)
EBS vs TLPH Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, TLPH has a market cap of 61.8M. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while TLPH trades at $1.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas TLPH's P/E ratio is -3.84. In terms of profitability, EBS's ROE is -0.36%, compared to TLPH's ROE of -0.87%. Regarding short-term risk, EBS is less volatile compared to TLPH. This indicates lower risk in terms of short-term price fluctuations for EBS.Check TLPH's competition here
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT)
EBS vs ZYBT Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, ZYBT has a market cap of 61.6M. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while ZYBT trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas ZYBT's P/E ratio is -6.32. In terms of profitability, EBS's ROE is -0.36%, compared to ZYBT's ROE of -0.27%. Regarding short-term risk, EBS is less volatile compared to ZYBT. This indicates lower risk in terms of short-term price fluctuations for EBS.Check ZYBT's competition here
The Valens Company Inc. (NASDAQ: VLNS)
EBS vs VLNS Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas VLNS's P/E ratio is -1.03. In terms of profitability, EBS's ROE is -0.36%, compared to VLNS's ROE of N/A. Regarding short-term risk, EBS is less volatile compared to VLNS. This indicates lower risk in terms of short-term price fluctuations for EBS.Check VLNS's competition here
InterCure Ltd. (NASDAQ: INCR)
EBS vs INCR Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, INCR has a market cap of 60.7M. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while INCR trades at $5.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas INCR's P/E ratio is -4.92. In terms of profitability, EBS's ROE is -0.36%, compared to INCR's ROE of -0.09%. Regarding short-term risk, EBS is less volatile compared to INCR. This indicates lower risk in terms of short-term price fluctuations for EBS.Check INCR's competition here
DURECT Corporation (NASDAQ: DRRX)
EBS vs DRRX Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas DRRX's P/E ratio is -4.44. In terms of profitability, EBS's ROE is -0.36%, compared to DRRX's ROE of -1.40%. Regarding short-term risk, EBS is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for EBS.Check DRRX's competition here
Jupiter Wellness, Inc. (NASDAQ: JUPW)
EBS vs JUPW Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas JUPW's P/E ratio is -2.41. In terms of profitability, EBS's ROE is -0.36%, compared to JUPW's ROE of -3.04%. Regarding short-term risk, EBS is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for EBS.Check JUPW's competition here
Qilian International Holding Group Limited (NASDAQ: QLI)
EBS vs QLI Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas QLI's P/E ratio is -4.92. In terms of profitability, EBS's ROE is -0.36%, compared to QLI's ROE of -0.16%. Regarding short-term risk, EBS is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for EBS.Check QLI's competition here
Rockwell Medical, Inc. (NASDAQ: RMTI)
EBS vs RMTI Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, RMTI has a market cap of 34.1M. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while RMTI trades at $8.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas RMTI's P/E ratio is -6.44. In terms of profitability, EBS's ROE is -0.36%, compared to RMTI's ROE of -0.14%. Regarding short-term risk, EBS is more volatile compared to RMTI. This indicates higher risk in terms of short-term price fluctuations for EBS.Check RMTI's competition here
HEXO Corp. (NASDAQ: HEXO)
EBS vs HEXO Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas HEXO's P/E ratio is -0.26. In terms of profitability, EBS's ROE is -0.36%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, EBS is less volatile compared to HEXO. This indicates lower risk in terms of short-term price fluctuations for EBS.Check HEXO's competition here
China Pharma Holdings, Inc. (AMEX: CPHI)
EBS vs CPHI Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, CPHI has a market cap of 29.5M. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while CPHI trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas CPHI's P/E ratio is -1.69. In terms of profitability, EBS's ROE is -0.36%, compared to CPHI's ROE of -0.17%. Regarding short-term risk, EBS is less volatile compared to CPHI. This indicates lower risk in terms of short-term price fluctuations for EBS.Check CPHI's competition here
TherapeuticsMD, Inc. (NASDAQ: TXMD)
EBS vs TXMD Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, TXMD has a market cap of 24.2M. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while TXMD trades at $2.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas TXMD's P/E ratio is 106.47. In terms of profitability, EBS's ROE is -0.36%, compared to TXMD's ROE of -0.01%. Regarding short-term risk, EBS is less volatile compared to TXMD. This indicates lower risk in terms of short-term price fluctuations for EBS.Check TXMD's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTH)
EBS vs CYTH Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas CYTH's P/E ratio is -0.80. In terms of profitability, EBS's ROE is -0.36%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, EBS is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for EBS.Check CYTH's competition here
Aytu BioPharma, Inc. (NASDAQ: AYTU)
EBS vs AYTU Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, AYTU has a market cap of 23.3M. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while AYTU trades at $2.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas AYTU's P/E ratio is -0.47. In terms of profitability, EBS's ROE is -0.36%, compared to AYTU's ROE of -0.53%. Regarding short-term risk, EBS is less volatile compared to AYTU. This indicates lower risk in terms of short-term price fluctuations for EBS.Check AYTU's competition here
Evoke Pharma, Inc. (NASDAQ: EVOK)
EBS vs EVOK Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas EVOK's P/E ratio is -7.97. In terms of profitability, EBS's ROE is -0.36%, compared to EVOK's ROE of -0.89%. Regarding short-term risk, EBS is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for EBS.Check EVOK's competition here
Optimi Health Corp. (NASDAQ: OPTH)
EBS vs OPTH Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, OPTH has a market cap of 15.6M. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while OPTH trades at $4.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas OPTH's P/E ratio is -3.37. In terms of profitability, EBS's ROE is -0.36%, compared to OPTH's ROE of -0.90%. Regarding short-term risk, EBS is less volatile compared to OPTH. This indicates lower risk in terms of short-term price fluctuations for EBS.Check OPTH's competition here
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)
EBS vs ACRX Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas ACRX's P/E ratio is -0.31. In terms of profitability, EBS's ROE is -0.36%, compared to ACRX's ROE of -0.87%. Regarding short-term risk, EBS is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for EBS.Check ACRX's competition here
Caring Brands, Inc. (NASDAQ: CABR)
EBS vs CABR Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, CABR has a market cap of 11.3M. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while CABR trades at $1.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas CABR's P/E ratio is -1.59. In terms of profitability, EBS's ROE is -0.36%, compared to CABR's ROE of -3.86%. Regarding short-term risk, EBS is less volatile compared to CABR. This indicates lower risk in terms of short-term price fluctuations for EBS.Check CABR's competition here
Agile Therapeutics, Inc. (NASDAQ: AGRX)
EBS vs AGRX Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas AGRX's P/E ratio is -0.89. In terms of profitability, EBS's ROE is -0.36%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, EBS is less volatile compared to AGRX. This indicates lower risk in terms of short-term price fluctuations for EBS.Check AGRX's competition here
Neoleukin Therapeutics, Inc. (NASDAQ: NLTX)
EBS vs NLTX Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas NLTX's P/E ratio is -0.28. In terms of profitability, EBS's ROE is -0.36%, compared to NLTX's ROE of -0.45%. Regarding short-term risk, EBS is less volatile compared to NLTX. This indicates lower risk in terms of short-term price fluctuations for EBS.Check NLTX's competition here
Lannett Company, Inc. (NYSE: LCI)
EBS vs LCI Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas LCI's P/E ratio is -0.04. In terms of profitability, EBS's ROE is -0.36%, compared to LCI's ROE of +1.66%. Regarding short-term risk, EBS is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for EBS.Check LCI's competition here
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)
EBS vs ADMP Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas ADMP's P/E ratio is -0.08. In terms of profitability, EBS's ROE is -0.36%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, EBS is less volatile compared to ADMP. This indicates lower risk in terms of short-term price fluctuations for EBS.Check ADMP's competition here
Gelteq Limited Ordinary Shares (NASDAQ: GELS)
EBS vs GELS Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, GELS has a market cap of 5M. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while GELS trades at $0.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas GELS's P/E ratio is -1.09. In terms of profitability, EBS's ROE is -0.36%, compared to GELS's ROE of -0.25%. Regarding short-term risk, EBS is less volatile compared to GELS. This indicates lower risk in terms of short-term price fluctuations for EBS.Check GELS's competition here
cbdMD, Inc. (AMEX: YCBD)
EBS vs YCBD Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, YCBD has a market cap of 4.9M. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while YCBD trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas YCBD's P/E ratio is -1.14. In terms of profitability, EBS's ROE is -0.36%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, EBS is less volatile compared to YCBD. This indicates lower risk in terms of short-term price fluctuations for EBS.Check YCBD's competition here
Mallinckrodt plc (AMEX: MNK)
EBS vs MNK Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas MNK's P/E ratio is -0.44. In terms of profitability, EBS's ROE is -0.36%, compared to MNK's ROE of -0.36%. Regarding short-term risk, EBS is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for EBS.Check MNK's competition here
Flora Growth Corp. (NASDAQ: FLGC)
EBS vs FLGC Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas FLGC's P/E ratio is -0.19. In terms of profitability, EBS's ROE is -0.36%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, EBS is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for EBS.Check FLGC's competition here
Universe Pharmaceuticals Inc. (NASDAQ: UPC)
EBS vs UPC Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, UPC has a market cap of 3.1M. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while UPC trades at $4.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas UPC's P/E ratio is -0.61. In terms of profitability, EBS's ROE is -0.36%, compared to UPC's ROE of -0.03%. Regarding short-term risk, EBS is less volatile compared to UPC. This indicates lower risk in terms of short-term price fluctuations for EBS.Check UPC's competition here
PLx Pharma Inc. (NASDAQ: PLXP)
EBS vs PLXP Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while PLXP trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas PLXP's P/E ratio is -0.22. In terms of profitability, EBS's ROE is -0.36%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, EBS is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for EBS.Check PLXP's competition here
InMed Pharmaceuticals Inc. (NASDAQ: INM)
EBS vs INM Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, INM has a market cap of 2.5M. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while INM trades at $1.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas INM's P/E ratio is -0.25. In terms of profitability, EBS's ROE is -0.36%, compared to INM's ROE of -1.35%. Regarding short-term risk, EBS is less volatile compared to INM. This indicates lower risk in terms of short-term price fluctuations for EBS.Check INM's competition here
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH)
EBS vs SHPH Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, SHPH has a market cap of 2.4M. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while SHPH trades at $3.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas SHPH's P/E ratio is -0.19. In terms of profitability, EBS's ROE is -0.36%, compared to SHPH's ROE of -1.57%. Regarding short-term risk, EBS is less volatile compared to SHPH. This indicates lower risk in terms of short-term price fluctuations for EBS.Check SHPH's competition here
Athenex, Inc. (NASDAQ: ATNX)
EBS vs ATNX Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while ATNX trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas ATNX's P/E ratio is -0.02. In terms of profitability, EBS's ROE is -0.36%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, EBS is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for EBS.Check ATNX's competition here
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA)
EBS vs SNOA Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, SNOA has a market cap of 2.1M. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while SNOA trades at $1.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas SNOA's P/E ratio is -1.14. In terms of profitability, EBS's ROE is -0.36%, compared to SNOA's ROE of -0.54%. Regarding short-term risk, EBS is less volatile compared to SNOA. This indicates lower risk in terms of short-term price fluctuations for EBS.Check SNOA's competition here
Procaps Group, S.A. (NASDAQ: PROCW)
EBS vs PROCW Comparison September 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 354M. In comparison, PROCW has a market cap of 2M. Regarding current trading prices, EBS is priced at $6.92 on the NYSE, while PROCW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 4.76, whereas PROCW's P/E ratio is N/A. In terms of profitability, EBS's ROE is -0.36%, compared to PROCW's ROE of -2.22%. Regarding short-term risk, EBS is more volatile compared to PROCW. This indicates higher risk in terms of short-term price fluctuations for EBS.Check PROCW's competition here